Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Tildrakizumab

Catalog #:   DHJ63102 Specific References (50) DATASHEET
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHJ63102

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NPF7

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MK-3222, SCH900222, CAS: 1326244-10-3

Clone ID

Tildrakizumab

Data Image
  • SDS-PAGE
    SDS PAGE for Tildrakizumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Comprehensive Post-marketing safety analysis of Tildrakizumab: insights from the FDA adverse event Reporting system., PMID:40512376

Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series., PMID:40488550

Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program., PMID:40442565

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors., PMID:40439875

Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use., PMID:40430215

Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies., PMID:40413278

Age of Onset Matters: Tildrakizumab Response in Early vs Late-Onset Psoriasis., PMID:40406970

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe., PMID:40396610

Complete Resolution of Residual Psoriasis by Adding Tapinarof Cream to Tildrakizumab: A Case Report., PMID:40391769

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry., PMID:40387427

A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment., PMID:40383754

Efficacy and safety of tildrakizumab in patients with early- vs late-onset psoriasis., PMID:40365708

Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis., PMID:40329054

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)., PMID:40266488

Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates., PMID:40162350

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis., PMID:40047295

Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review., PMID:40026108

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs., PMID:39969048

Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study., PMID:39847259

Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis., PMID:39833957

Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?, PMID:39797306

Editor's Highlights-February 2025., PMID:39791934

Demographics, Disease Characteristics, and Treatment Patterns of Patients with Plaque Psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in Poland., PMID:39768570

INDIVIDUAL ARTICLE: Psoriasis and Obesity: Optimizing Pharmacologic Treatment and Lifestyle Interventions., PMID:39761151

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial., PMID:39722400

Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada., PMID:39673433

Off-label dermatologic uses of IL-23 inhibitors., PMID:39647840

Successful treatment of psoriasis and lichen planus with tildrakizumab., PMID:39644480

Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study., PMID:39626647

Facial psoriasis treated with tildrakizumab., PMID:39611417

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)., PMID:39601368

The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial., PMID:39547392

Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis., PMID:39526612

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study., PMID:39462515

Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis., PMID:39458658

A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?, PMID:39453881

Off-Label Use of Tildrakizumab in Patients with Hidradenitis Suppurativa., PMID:39450621

Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study., PMID:39450612

Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis., PMID:39445319

Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient., PMID:39430645

Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study., PMID:39400048

Patients' Preferences Regarding Modes of Systemic Psoriasis Treatment - A Qualitative Study., PMID:39381162

Comparison table: Some drugs for plaque psoriasis., PMID:39302349

Drugs for plaque psoriasis., PMID:39302348

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series., PMID:39295833

Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data., PMID:39295829

Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?, PMID:39274452

The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target., PMID:39230202

A case of eczematous paradoxical reactions on the extremities during tildrakizumab treatment for plaque psoriasis., PMID:39229699

Effectiveness and safety of tildrakizumab in individuals with HIV and psoriasis: A case series., PMID:39226448

Datasheet

Document Download

Research Grade Tildrakizumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Tildrakizumab [DHJ63102]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only